Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.50 |
| ▸ | THRB | P10828 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29260785 | 0.82 | PARP1 (0.37) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL5171611 | 0.81 | PARP1 (0.46) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL28982560 | 0.81 | TDP1 (0.59) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL9450352 | 0.81 | PPOX (0.48) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL7806624 | 0.78 | PARP1 (0.47) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL7429649 | 0.78 | THRB (0.55) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL10424885 | 0.77 | PARP1 (0.42) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL5326248 | 0.77 | PARP1 (0.39) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL6468586 | 0.77 | PARP1 (0.50) | PARP1THRBTDP1MEN1POLB | |
| SCHEMBL29372946 | 0.76 | PARP1 (0.53) | PARP1THRBTDP1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271901-A | Alcohol-soluble environment-friendly printing ink and preparation method thereof | 厦门欧化实业有限公司 | 2024-07-02 | — | — | CN | claimed |
| EP-2373329-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | The Regents of the University of California (US) | 2011-10-12 | — | — | EP | claimed |
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-29 | — | — | US | claimed |
| WO-2010123527-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | WO | claimed |
| WO-1997043643-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA INDUCED MUCIN PRODUCTION: COMPOSITIONS AND TREATMENTS FOR CYSTIC FIBROSIS PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-11-20 | — | — | WO | claimed |
| JP-5163240-A | — | — | None | — | — | JP | disclosed |
| CN-118271901-A | Alcohol-soluble environment-friendly printing ink and preparation method thereof | 厦门欧化实业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-2066673-B1 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE CORP (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| CN-102036990-B | Novel tyrosine kinase inhibitors | CHEMBRIDGE CORP. (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-1102643-A | Substituted derivatives of diaminophthalimide | CIBA GEIGY AG (CH) | 1995-05-17 | — | — | CN | disclosed |
| CN-1102643-A | Substituted derivatives of diaminophthalimide | CIBA GEIGY AG (CH) | 1995-05-17 | — | — | CN | disclosed |
| EP-0516588-B1 | Substituted diaminophtalimides and analogues | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
| EP-0600830-A1 | Substituted derivatives of diaminophthalimide as protein-tyrosine kinase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| JP-H05163240-A | SUBSTITUTED DIAMINOPHTHALIMIDE AND ANALOGUE | CIBA GEIGY AG | 1993-06-29 | — | — | JP | disclosed |
| CN-1067052-A | The diaminophthalimides and the analogue thereof that replace | CIBA GEIGY AG (CH) | 1992-12-16 | — | — | CN | disclosed |
| CN-1067052-A | The diaminophthalimides and the analogue thereof that replace | CIBA GEIGY AG (CH) | 1992-12-16 | — | — | CN | disclosed |
| EP-0516588-A1 | Substituted diaminophtalimides and analogues | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | EGFR, HDGF, HGF | PARP1 4324/4885THRB 819/4885TDP1 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.